EGFR and lung adenocarcinoma: Our findings suggest that SII is associated with all-cause mortality in patients with stages IIIB–IV EGFR-mutated lung adenocarcinoma, regardless of mutation subtype, indicating the potential of SII as a prognostic blood biomarker.